Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of ALXN1830 (orilanolimab) in warm autoimmune hemolytic anemia
2019-004055-37Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing ALXN1830 (orilanolimab) with Placebo (2 arms). Primary endpoint: Hemoglobin response without treatment escalation or transfusions. Started May 2020; status: terminated.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2019-004055-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004055-37.